Diroximel fumarate is a drug used for the treatment of relapsing forms of Multiple Sclerosis (MS). Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life.
- Mechanism
- Curator reviewed · 5 references
Currently, the mechanism of action of this drug in MS is not fully understood. Diroximel fumarate is hypothesized to regulate cell signaling pathways, causing beneficial immune and neuroprotective effects. Monomethyl fumarate (MMF) is the active metabolite of diroximel fumarate, and activates the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway in humans. This pathway occurs as a response to oxidative stress in cells.
In addition to the above, MMF is a nicotinic acid receptor agonist in the laboratory setting. The relevance of this finding to the treatment of MS is unknown at this time. The mechanism by which this drug leads to less gastrointestinal effects is purported to be due to its lack of a methanol leaving group in its chemical structure, and substitution with inert 2-hydroxyethyl succinimide.
- Primary indication
- Diroximel fumarate is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults; specifically active secondary progressive disease and clinically isolated syndrome, as well as relapsing-remitting MS.Curator reviewed · 3 structured indications
- Formula / weight
- C11H13NO6 · 255.226 g/mol (avg)
- First approval
- United States, 2019 · European Union, 2022
- Code names
- ALK8700 · ALKS-8700 · BIIB-098 · RDC-5108
- Brand names
Resolves to
YIMYDTCOUQIDMT-SNAWJCMRSA-NSMILESCOC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=OWhat you can answer from here — as of June 15, 2026
Which drugs share a target with Diroximel fumarate, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account